Results 151 to 160 of about 2,752 (194)
Some of the next articles are maybe not open access.
Indacaterol–Glycopyrronium for COPD
New England Journal of Medicine, 2016letter
Franssen, Frits M. E. +3 more
openaire +5 more sources
Efficacy of Once-Daily Indacaterol Relative to Alternative Bronchodilators in COPD: A Patient-Level Mixed Treatment Comparison [PDF]
Value in Health, 2012 ObjectiveIndacaterol was evaluated versus placebo, formoterol, and salmeterol in randomized controlled trials. No direct comparisons, however, are available for indacaterol 150 μg with formoterol or indacaterol 300 μg with salmeterol.
Shannon Cope +2 more
exaly +2 more sources
Bronchodilator effects of indacaterol and formoterol in patients with COPD
Pulmonary Pharmacology and Therapeutics, 2009 Resting inspiratory capacity (IC) reflects static hyperinflation in chronic obstructive pulmonary disease (COPD). This study compared the effects of formoterol and indacaterol, a novel once-daily ultra-long-acting beta(2)-agonist (or ultra-LABA), on resting IC and forced expiratory volume in 1 s (FEV(1)).Thirty patients with COPD (mean FEV(1)/FVC 0.49,
J Beier
exaly +4 more sources
The safety of indacaterol for the treatment of COPD
Expert Opinion on Drug Safety, 2018Bronchodilators, namely long-acting inhaled β2-agonists and long-acting muscarinic antagonists, are the first-line medications for chronic obstructive pulmonary disease (COPD). The safety of these medicines is of great concern since COPD patients usually have other co-morbidities such as cardio- and cerebrovascular diseases.
Evgenios I, Metaxas, Evangelos, Balis
openaire +2 more sources
Drug and Therapeutics Bulletin, 2012
▼Indacaterol powder for inhalation (Onbrez Breezhaler – Novartis) is a long-acting beta2 agonist, licensed for once-daily use as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). In this article, we consider the evidence for indacaterol and how its use fits with current management strategies for COPD.
openaire +2 more sources
▼Indacaterol powder for inhalation (Onbrez Breezhaler – Novartis) is a long-acting beta2 agonist, licensed for once-daily use as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). In this article, we consider the evidence for indacaterol and how its use fits with current management strategies for COPD.
openaire +2 more sources
Metabolism and Pharmacokinetics of Indacaterol in Humans
Drug Metabolism and Disposition, 2012The metabolism, pharmacokinetics, and excretion of [(14)C]indacaterol were investigated in healthy male subjects. Although indacaterol is administered to patients via inhalation, the dose in this study was administered orally. This was done to avoid the complications and concerns associated with the administration of a radiolabeled compound via the ...
Mark, Kagan +3 more
openaire +2 more sources
Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma
Drugs, 2021Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) is a fixed-dose combination of the long-acting β2 agonist (LABA) indacaterol, the long-acting muscarinic antagonist (LAMA) glycopyrronium and the inhaled corticosteroid (ICS) mometasone furoate (hereafter referred to as mometasone) delivered via a capsule-based dry-powder inhaler.
openaire +2 more sources
Indacaterol/glycopyrronium: a dual bronchodilator for COPD
Drug Discovery Today, 2018Indacaterol/glycopyrronium (IND/GLY) 110/50mcg was the first once-daily, long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD). Development of IND/GLY was driven by the need to improve the standard of care for patients with
Donald, Banerji +2 more
openaire +2 more sources
Drugs, 2010
Indacaterol is a long-acting β₂-adrenoceptor agonist that is available in the EU for the maintenance treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). Indacaterol has a 24-hour bronchodilatory effect, which allows for once-daily administration.
openaire +2 more sources
Indacaterol is a long-acting β₂-adrenoceptor agonist that is available in the EU for the maintenance treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). Indacaterol has a 24-hour bronchodilatory effect, which allows for once-daily administration.
openaire +2 more sources
The Preclinical Pharmacology of Indacaterol
2013The preclinical pharmacological profile of indacaterol, a novel, chirally pure inhaled beta(2) adrenoceptor agonist, is described in this chapter. In various in vitro systems, indacaterol is close to a full agonist at the human β2-adrenoceptor with nanomolar potency.
Alexandre Trifilieff +2 more
openaire +1 more source